Stocks and Investing Stocks and Investing
Thu, October 4, 2018
Wed, October 3, 2018

David Risinger Maintained (AMRX) at Buy with Decreased Target to $24 on, Oct 3rd, 2018


Published on 2024-10-26 09:09:31 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Buy with Decreased Target from $26 to $24 on, Oct 3rd, 2018.

David has made no other calls on AMRX in the last 4 months.



There are 4 other peers that have a rating on AMRX. Out of the 4 peers that are also analyzing AMRX, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Dewey Steadman of "Canaccord Genuity" Maintained at Hold with Increased Target to $21 on, Tuesday, August 14th, 2018
  • Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $20 on, Friday, August 10th, 2018


These are the ratings of the 2 analyists that currently disagree with David


  • David Buck of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $28 on, Wednesday, August 22nd, 2018
  • Randall Stanicky of "RBC Capital" Upgraded from Hold to Buy on, Monday, August 13th, 2018
Contributing Sources